Navigation Links
Novan Announces Promising Results of SB204 Clinical Study
Date:5/30/2013

DURHAM, N.C., May 30, 2013 /PRNewswire/ -- Novan Therapeutics, today announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes)  in the skin of healthy volunteers.  This study in combination with Novan's earlier findings regarding sebum production, suggests the formulation may be capable of targeting multiple factors in acne.

(Logo: http://photos.prnewswire.com/prnh/20130228/NE68367LOGO )

The Phase 1, 30-subject study was conducted by Dr. James Leyden (KGL, Inc.). This predictive human model has been used to demonstrate the activity of anti-acne therapies like traditional oral antibiotics and topical antibiotics such as clindamycin.  In this study, twice daily administration of the topical product was safe and "the treatment was extremely well tolerated," added Dr. Leyden.  Several subjects demonstrated a greater than 90 percent reduction of P. acnes when treated with SB204; no vehicle-treated subjects exhibited such a response.  A statistically significant difference (p < 0.05) in P. acnes counts was observed between active and vehicle after two weeks.

Acne is the most common skin disease in the United States, affecting more than 50 million people.  Antibiotics have been a mainstay for dermatologists due to the ability to reduce P. acnes colonization in the skin and the documented ability to treat inflammatory lesions in acne patients.  However, monotherapy usage of these drugs has slowed due to the onset of antibiotic resistance.  Nitric oxide is an antimicrobial with a low propensity for resistance and is part of the human body's natural immune response to bacteria.  "These unique properties of nitric oxide, in conjunction with the potential to reduce sebum, provide the basis for our belief that SB204 has the possibility to transform acne care," says Dr. Nathan Stasko , Novan President .

"I have always said the 'Holy Grail' of acne treatments would be a topical that can influence sebum production or the physicochemical properties of sebum.  If you can do that, the ability to kill P. acnes is icing on the cake," said Dr. Leyden.

SB204 is currently being examined in a Phase 2 study for the treatment of acne.  Results of that study are expected early 2014.

About Novan, Inc.

Novan Inc., based in the Research Triangle Park area of North Carolina, is a clinical-stage drug development company focused on topical delivery of nitric oxide.  Nitric oxide, one of the most studied molecules in human physiology, has been shown to exhibit anti-microbial activity and to promote vasodilation, regulate inflammation, stimulate tissue repair, and even eradicate cancer cells.  The company's proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms.  Novan is currently developing innovative, first-in-class therapies for the field of dermatology. 

For more information, please contact:

Julia Brannan
Pascale Communications
201-725-7375
novan@pascalecommunications.com
www.novantherapeutics.com

 


'/>"/>
SOURCE Novan Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novans SB204 Could Be First Topical Sebum Inhibitor
2. Sequenom Announces License And Marketing Agreements With Laboratoire Cerba In France
3. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
4. DMH International Announces EMR Integration to TouchPACS
5. Health Diagnostic Laboratory, Inc. Announces Diabetes Prevention & Management Panel for Early Detection and Treatment of Disease
6. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
7. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
8. VUCA Health Announces Rapid Adoption of its MedsOnCue Digital Patient Engagement Solution Supporting Health Literacy by Innovative Pharmacies across 19 States
9. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
10. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
11. ReproCELL Inc. Announces Approval for Listing on the Osaka Stock Exchange JASDAQ Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... new report "Global Diagnostic Ultrasound Devices Market Assessment & Forecast: 2015-2019" ... diagnostic ultrasound devices market was valued at US$ 5,381.1 million in ... at a CAGR of 6.8% from 2015 to 2019. The ... for six geographies of North America , ... Latin America , Middle-East and ...
(Date:2/9/2016)... The global prefilled syringes market accounted for $3,905.1 million ... with a CAGR of 12.9% during 2015-2020. Among the ... global prefilled syringes market, with 90.1% share in 2014. ... global market of prefilled syringes is up surging with ... demand for vaccines, increasing prevalence of chronic and lifestyle ...
(Date:2/9/2016)... report "Global Blood Monitoring & Cardiac Monitoring Devices Market Assessment & ... that global market for blood monitoring & cardiac monitoring devices was ... to US$ 24,830.1 million by 2019 at a CAGR of 6.8% ... Europe , Asia-Pacific , ... Africa . The three major factors determining growth ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, ... of a new charity campaign. As part of their ongoing community involvement program, ... the belief that children deserve a voice, and in the spirit of neighbors ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... A man who has struggled to quit ... Freedom Laser Therapy , was determined to find solutions to his problems – and he ... Inventors Digest is ready to introduce his breakthrough inventions to the world and better ...
(Date:2/8/2016)... York, NY (PRWEB) , ... February 08, 2016 , ... ... are too much to handle, you are not alone. According to the Center for ... include heart disease, stroke, type 2 diabetes and certain types of cancer, some of ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Steve Helwig ... with a vital new community enrichment program, has teamed up with Citizens Opposed to ... children suffering from intimate abuse. To support all those victimized by the fear of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency Dennis ... FL area, has initiated a fundraiser for a two year old little girl ... after Christmas. To support this beautiful child who is facing life’s journey without ...
Breaking Medicine News(10 mins):